Patents by Inventor Robert G. Korneluk

Robert G. Korneluk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20210322545
    Abstract: The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory or immunomodulatory compound or oncolytic virus.
    Type: Application
    Filed: February 23, 2017
    Publication date: October 21, 2021
    Inventors: Robert G. KORNELUK, Eric C. LACASSE, Shawn T. BEUG, Vera A. TANG
  • SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20200384103
    Abstract: The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.
    Type: Application
    Filed: October 10, 2019
    Publication date: December 10, 2020
    Inventors: Robert G. KORNELUK, Eric C. LACASSE, Shawn T. BEUG, Vera A. TANG
  • SMC combination therapy for the treatment of cancer
    Patent number: 10441654
    Abstract: The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: October 15, 2019
    Assignee: Children's Hospital of Eastern Ontario Research Institute Inc.
    Inventors: Robert G. Korneluk, Eric C. Lacasse, Shawn T. Beug, Vera A. Tang
  • SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20170239347
    Abstract: The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.
    Type: Application
    Filed: January 26, 2015
    Publication date: August 24, 2017
    Applicants: Children's Hospital of Eastern Ontario Research Institute Inc., Children's Hospital of Eastern Ontario Research Institute Inc.
    Inventors: Robert G. KORNELUK, Eric C. LACASSE, Shawn T. BEUG, Vera A. TANG
  • XIAP THERAPY
    Publication number: 20110318307
    Abstract: The invention features methods, compositions and kits for the treatment of retinal degenerative disorders.
    Type: Application
    Filed: February 23, 2011
    Publication date: December 29, 2011
    Inventors: Robert G. Korneluk, Catherine Tsilfidis, Peter Liston
  • Diagnostic marker for interferon responsiveness in multiple sclerosis
    Patent number: 8021840
    Abstract: Disclosed is a method of determining interferon responsiveness in a patient suffering from multiple sclerosis. The method comprises determining an amount of a XAF-1 gene expression level in a blood sample, which is obtained from the patient undergoing interferon therapy. The amount of the XAF-1 gene expression level in the blood sample is then correlated with the responsiveness of the patient to the interferon.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: September 20, 2011
    Assignee: Dianovix, Inc.
    Inventors: Virender Bhan, Andrea Hebb, Martin Holcik, Robert G. Korneluk, Craig Moore, George Robertson
  • METHOD FOR DIFFERENTIATING BETWEEN MULTIPLE SCLEROSIS SUBTYPES
    Publication number: 20110136133
    Abstract: Disclosed herein is a method for differentiating between multiple sclerosis subtypes in a patient. The method comprises a) determining an amount of an IAP gene expression level in a blood sample obtained from the patient; and b) correlating the amount of the IAP gene expression level in the blood sample with the presence of a multiple sclerosis subtype in the patient.
    Type: Application
    Filed: November 17, 2010
    Publication date: June 9, 2011
    Applicant: Dianovix, Inc.
    Inventors: Virender BHAN, John Gillard, Andrea Hebb, Martin Holcik, Robert G. Korneluk, George Robertson
  • Method for differentiating between multiple sclerosis subtypes
    Patent number: 7858309
    Abstract: Disclosed herein is a method for differentiating between multiple sclerosis subtypes in a patient. The method comprises a) determining an amount of an IAP gene expression level in a blood sample obtained from the patient; and b) correlating the amount of the IAP gene expression level in the blood sample with the presence of a multiple sclerosis subtype in the patient.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: December 28, 2010
    Assignee: Dianovix, Inc.
    Inventors: Virender Bhan, John W. Gillard, Andrea Hebb, Martin Holcik, Robert G. Korneluk, George Robertson
  • Mammalian IAP gene family, primers, probes and detection methods
    Patent number: 7776552
    Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primer and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: August 17, 2010
    Assignee: University of Ottawa
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird, Peter Liston
  • DETECTION AND MODULATION OF IAPs AND NAIP FOR THE DIAGNOSIS AND TREATMENT OF PROLIFERATIVE DISEASE
    Publication number: 20090142334
    Abstract: Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids, IAP fragments, and antibodies which specifically bind IAP polypeptides.
    Type: Application
    Filed: April 28, 2008
    Publication date: June 4, 2009
    Applicant: AEGERA THERPEUTICS, INC.
    Inventors: Robert G. Korneluk, Alexander E. Mackenzie, Peter Liston, Stephen Baird, Benjamin K. Tsang, Christine Pratt
  • Antisense IAP oligonucleotides and uses thereof
    Patent number: 7294713
    Abstract: The present invention feature antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: November 13, 2007
    Assignee: Aegera Therapeutics Inc.
    Inventors: Robert G. Korneluk, Eric LaCasse, Stephen Baird, Martin Holcik, Sean Young
  • Detection and modulation of IAPs and NAIP for the diagnosis and treatment of proliferative disease
    Publication number: 20070219360
    Abstract: Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids, IAP fragments, and antibodies which specifically bind IAP polypeptides.
    Type: Application
    Filed: August 25, 2006
    Publication date: September 20, 2007
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Peter Liston, Stephen Baird, Benjamin K. Tsang, Christine Pratt
  • Use of neuronal apoptosis inhibitor protein (NAIP)
    Patent number: 7235372
    Abstract: The invention provides a novel NAIP nucleic and sequences. Also provided are anti-NAIP antibodies and methods for modulating apoptosis and detecting compounds which modulate apoptosis.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: June 26, 2007
    Assignee: University of Ottawa
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Natalie Roy, George Robertson, Katsu Tamai
  • Detection and modulation of IAPs and NAIP for the diagnosis and treatment of proliferative disease
    Patent number: 7087584
    Abstract: Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: August 8, 2006
    Assignee: Aegera Therapeutics Inc.
    Inventors: Robert G. Korneluk, Alexander E. Mackenzie, Peter Liston, Stephen Baird, Benjamin K. Tsang, Christine Pratt
  • Mammalian IAP gene family, primers, probes and detection methods
    Patent number: 7067281
    Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; substantially pure polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primers and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: June 27, 2006
    Assignee: Aegera Therapeutics, Inc.
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird, Peter Liston
  • Use of neuronal apoptosis inhibitor protein (NAIP)
    Patent number: 6994957
    Abstract: The invention provides NAIP nucleic acid and sequences. Also provided are anti-NAIP antibodies and methods for modulating apoptosis and detecting compounds which modulate apoptosis.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: February 7, 2006
    Assignee: University of Ottawa
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Natalie Roy, George Robertson
  • Mammalian IAP gene family, primers, probes, and detection methods
    Patent number: 6977158
    Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; substantially pure polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primers and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: December 20, 2005
    Assignee: University of Ottawa
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird
  • XAF genes and polypeptides: methods and reagents for modulating apoptosis
    Patent number: 6946544
    Abstract: The invention provides novel XAF nucleic acid sequences. Also provided are XAF polypeptides, anti-XAF antibodies, and methods for modulating apoptosis and detecting compounds which modulate apoptosis.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: September 20, 2005
    Assignee: Aegera Therapeutics Inc.
    Inventors: Robert G. Korneluk, Katsuyuki Tamai, Peter Liston, Alexander E. MacKenzie
  • Methods and compounds for modulating male fertility
    Patent number: 6797473
    Abstract: The invention features methods and reagents useful for the treatment of excessive or insufficient apoptosis in cells, and, particularly, in germ-line cells. The invention is useful in treating testicular cancers, cancers of germ-line cells, cancers in non-germ-line cell tissues, infertility (e.g., male infertility), and for birth control (e.g., male birth control).
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: September 28, 2004
    Assignee: University of Ottawa
    Inventors: Robert G. Korneluk, Mark Lagacé
  • Methods for enhancing survival of a neuron
    Patent number: 6709866
    Abstract: NAIP and IAP polypeptides prevent neuronal cell death caused by ischemia, neurodegenerative conditions, and axotomy. The invention provides methods for neuroprotection by the prevention of cell death and kits and methods for the identification of neuroprotective therapeutic compounds.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: March 23, 2004
    Assignee: Aegera Therapeutics, Inc.
    Inventors: George S. Robertson, Robert G. Korneluk, Alexander E. MacKenzie, Daigen Xu, Stephen J. Crocker